Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Senzime AB ( (SE:SEZI) ) has shared an announcement.
Senzime AB announced that its licensee, Fukuda Denshi, has obtained FDA and UKCA approvals to introduce the HN-100 neuromuscular transmission module in the US and UK. This development is significant for Senzime as it expands Fukuda’s market reach, leveraging Senzime’s TetraGraph® technology, and potentially increasing revenue through manufacturing and royalty agreements.
More about Senzime AB
Senzime is a leading medical device company established in 1999, specializing in precision-based monitoring systems that enhance perioperative patient safety. Their flagship product, the TetraGraph® system, is renowned for its accuracy in monitoring neuromuscular transmission during surgery. Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market and the US OTCQX Market.
Average Trading Volume: 320,909
Current Market Cap: SEK843.6M
For detailed information about SEZI stock, go to TipRanks’ Stock Analysis page.